The Multinational Association of Supportive Care in Cancer (MASCC) shared a post on LinkedIn:
“Our first episode of the Supportive CARE DIGEST is now available.
Dr. Martin Harutyunyan reviews the New England Journal of Medicine Phase 2 trial of ponsegromab, a GDF‑15–neutralizing antibody showing promising results in cancer cachexia. The study reported improvements in weight, appetite, anorexia symptoms, physical activity, and skeletal muscle, along with a favorable safety profile.
Watch the episode and stay connected with MASCC for updates in supportive cancer care.”